After selling its spinout to Bayer in a $875M-plus deal, NeRRe Therapeutics grabs $28M for some 'unfinished business'
Some biotech CEOs find themselves out of jobs following a buyout. Not Mary Kerr.
In fact, after Bayer dished out $425 million in cash to buy KaNDy Therapeutics and its menopause treatment last August — which was spun out from NeRRe Therapeutics and run by that exact same team — her entire crew quickly got back to work.
Like the drug that Bayer bought (dubbed NT-814), the three other drugs sitting in NeRRe’s pipeline are neurokinin-targeting compounds that had originally hailed from GlaxoSmithKline. Among them, orvepitant for chronic cough was the lead candidate, positioned just slightly ahead of NT-814 as the lead candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.